Senju Pharmaceuticals Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Osaka Japan (1947)

Organization Overview

First Clinical Trial
2009
NCT00836485
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Senju Pharmaceutical Co., Ltd. | Senju USA, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

131 iodine (2 trials)

Fonadelpar (3 trials)

Drugs in Phase 2 Trials (5)

ketotifen (zaditor) (1 trial)

methylcellulose (1 trial)

mt-0814 (1 trial)

olopatadine (patanol) (1 trial)

sjp-0132 (1 trial)

Drugs in Phase 1 Trials (1)

sjp-0008 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chalazion (Phase 3)

Conjunctivitis (Phase 2)

Conjunctivitis, Allergic (Phase 2)

Disease (Phase 2)

Dry Eye Syndromes (Phase 3)

Eye Diseases (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 8